论文部分内容阅读
目的总结含硼替佐米方案治疗多发性骨髓瘤(MM)的药物经济学价值,为临床决策提供参考,促进临床合理用药。方法检索Embase、MEDLINE、中国期刊全文数据库2010—2016年发表的含硼替佐米方案治疗MM的药物经济学研究,综述药物经济学分析结果。结果纳入研究文献共14篇,分析结果显示,含硼替佐米方案治疗MM的药物经济学研究结果差异有统计学意义(P<0.05)。结论由于缺乏直接证据,含硼替佐米方案治疗MM的药物经济学研究不能直接为临床决策提供参考,需进一步进行研究,且需大力开展中国药物经济学研究。
OBJECTIVE: To summarize the pharmacological value of bortezomib in the treatment of multiple myeloma (MM), to provide a reference for clinical decision-making and to promote clinical rational use of drugs. Methods Embase, MEDLINE, Chinese Journal Full-text Database Pharmacokinetic studies of MM with bortezomib were published in 2010-2016, and the results of pharmacoeconomic analysis were reviewed. The results were included in the study of a total of 14 articles, the analysis showed that bortezomib regimen in the treatment of MM drug economics differences were statistically significant (P <0.05). Conclusion Due to the lack of direct evidence, pharmacoeconomic studies of bortezomib in the treatment of MM can not directly provide a reference for clinical decision-making and need to be further studied, and the study of Chinese pharmacoeconomics needs to be vigorously carried out.